Table 1.
Patient characteristics and clinical data (n = 28)
| Characteristics | Value |
|---|---|
| Median age (years) [4] | 69 (54–94)* |
| Female/male | 8/20 |
| Therapy | |
| Rituximab monotherapy | 3 |
| Rituximab maintenance† | 12 |
| Bendamustine–rituximab | 3 |
| Bendamustine–obinutuzumab | 2 |
| R-CHOP | 8 |
| Type of Non-Hodgkin lymphoma | |
| Diffuse large B-cell lymphoma | 8 |
| Follicular lymphoma | 14 |
| Marginal zone lymphoma | 6 |
| Treatment | |
| Time from last mAbs dose to first vaccination (days) | 25 (9–162) |
| No. of therapy cycles in latest treatment line before vaccination | 9 (3–19) |
| Treatment (primary/salvage) | 27/1 |
| Laboratory data | |
| White blood cell count (× 10³/µL) | 4.700 (2.200–8.600) |
| Absolute lymphocyte count (× 10³/µL) | 0.96 (0.22–2.24) |
| Immunoglobulin level (mg/dL) | |
| IgG | 866 (338–1340) |
| IgA | 118 (<27 to 271) |
| IgM | 26 (<17 to 796) |
| Immunophenotyping | |
| CD3 count (% of lymphocytes) | 81 (51–98) |
| CD4 count (% of CD3+ cells) | 41 (16–76) |
| CD8 count (% of CD3+ cells) | 49 (22–78) |
| CD19 count (% of lymphocytes) | 0 (0–12) |
CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone; mAbs=monoclonal antibodies; R=rituximab.
⁎
Values are expressed as the number of patients or median (range).
†
Four patients after R-CHOP, one patient after R-CVP, seven patients after bendamustine–rituximab.